APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Viral Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Viral Vaccines Market Outlook and Growth Opportunities 2026

Report ID 174046490426 December 2025198 pages

Choose your research edition.

Industry ResearchViral Vaccines Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vaccines Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Viral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vaccines Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Viral Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Viral Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Viral Vaccines market include GSK, Sanofi, Novartis, Merck, Pfizer, Bayer, Zoetis, Johnson and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Viral Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Viral Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Viral Vaccines Segment by Company

GSK

Sanofi

Novartis

Merck

Pfizer

Bayer

Zoetis

Johnson

CSL

AstraZeneca

Viral Vaccines Segment by Type

Attenuated Vaccine

Inactivated Vaccine

Viral Vaccines Segment by Application

Research Institute

Hospital

Pharmaceutical Factory

Others

Viral Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viral Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Viral Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viral Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Viral Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Viral Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Vaccines industry.

Chapter 3: Detailed analysis of Viral Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Viral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Viral Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viral Vaccines Industry Trends Table 2. Viral Vaccines Industry Drivers Table 3. Viral Vaccines Industry Opportunities and Challenges Table 4. Viral Vaccines Industry Restraints Table 5. Global Viral Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viral Vaccines Revenue Share by Company (2021-2026) Table 7. Global Viral Vaccines Sales Volume by Company (W Tons) & (2021-2026) Table 8. Global Viral Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Viral Vaccines Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Viral Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Viral Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Viral Vaccines Company, Product Type & Application Table 13. Global Viral Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Viral Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Attenuated Vaccine Table 18. Significant Companies of Inactivated Vaccine Table 19. Global Viral Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (W Tons) Table 20. Global Viral Vaccines Sales Volume by Type (2021-2026) & (W Tons) Table 21. Global Viral Vaccines Sales Volume by Type (2027-2032) & (W Tons) Table 22. Global Viral Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Viral Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Viral Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Viral Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Viral Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Viral Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Viral Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Research Institute Table 30. Significant Companies of Hospital Table 31. Significant Companies of Pharmaceutical Factory Table 32. Significant Companies of Others Table 33. Global Viral Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (W Tons) Table 34. Global Viral Vaccines Sales Volume by Application (2021-2026) & (W Tons) Table 35. Global Viral Vaccines Sales Volume by Application (2027-2032) & (W Tons) Table 36. Global Viral Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global Viral Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global Viral Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Viral Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Viral Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Viral Vaccines Sales Value Share by Application (2021-2026) Table 42. Global Viral Vaccines Sales Value Share by Application (2027-2032) Table 43. Global Viral Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Table 44. Global Viral Vaccines Sales by Region (2021-2026) & (W Tons) Table 45. Global Viral Vaccines Sales Market Share by Region (2021-2026) Table 46. Global Viral Vaccines Sales by Region (2027-2032) & (W Tons) Table 47. Global Viral Vaccines Sales Market Share by Region (2027-2032) Table 48. Global Viral Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Viral Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Viral Vaccines Sales Value Share by Region (2021-2026) Table 51. Global Viral Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Viral Vaccines Sales Value Share by Region (2027-2032) Table 53. Global Viral Vaccines Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Viral Vaccines Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Viral Vaccines Sales by Country: 2021 VS 2025 VS 2032 (W Tons) Table 56. Global Viral Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Viral Vaccines Sales by Country (2021-2026) & (W Tons) Table 58. Global Viral Vaccines Sales Market Share by Country (2021-2026) Table 59. Global Viral Vaccines Sales by Country (2027-2032) & (W Tons) Table 60. Global Viral Vaccines Sales Market Share by Country (2027-2032) Table 61. Global Viral Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Viral Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global Viral Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Viral Vaccines Sales Value Market Share by Country (2027-2032) Table 65. GSK Company Information Table 66. GSK Business Overview Table 67. GSK Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. GSK Viral Vaccines Product Portfolio Table 69. GSK Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Sanofi Viral Vaccines Product Portfolio Table 74. Sanofi Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Novartis Viral Vaccines Product Portfolio Table 79. Novartis Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Merck Viral Vaccines Product Portfolio Table 84. Merck Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Pfizer Viral Vaccines Product Portfolio Table 89. Pfizer Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Bayer Viral Vaccines Product Portfolio Table 94. Bayer Recent Development Table 95. Zoetis Company Information Table 96. Zoetis Business Overview Table 97. Zoetis Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. Zoetis Viral Vaccines Product Portfolio Table 99. Zoetis Recent Development Table 100. Johnson Company Information Table 101. Johnson Business Overview Table 102. Johnson Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Johnson Viral Vaccines Product Portfolio Table 104. Johnson Recent Development Table 105. CSL Company Information Table 106. CSL Business Overview Table 107. CSL Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. CSL Viral Vaccines Product Portfolio Table 109. CSL Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Viral Vaccines Sales (W Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. AstraZeneca Viral Vaccines Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Viral Vaccines Distributors List Table 118. Viral Vaccines Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Viral Vaccines Product Image Figure 2. Global Viral Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Viral Vaccines Sales (2021-2032) & (W Tons) Figure 5. Global Viral Vaccines Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Viral Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Attenuated Vaccine Image Figure 10. Inactivated Vaccine Image Figure 11. Global Viral Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (W Tons) Figure 12. Global Viral Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Viral Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Viral Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Viral Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Viral Vaccines Sales Value Share by Type (2021-2032) Figure 17. Research Institute Image Figure 18. Hospital Image Figure 19. Pharmaceutical Factory Image Figure 20. Others Image Figure 21. Global Viral Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (W Tons) Figure 22. Global Viral Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Viral Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global Viral Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Viral Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Viral Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global Viral Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Tons) Figure 28. Global Viral Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Viral Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Viral Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Viral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America Viral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Viral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Viral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Viral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Viral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Viral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America Viral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Viral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Viral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Viral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Viral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Viral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Viral Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Viral Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated Vaccine
  • Inactivated Vaccine
Applications
  • Research Institute
  • Hospital
  • Pharmaceutical Factory
  • Others
Companies covered
  • GSK
  • Sanofi
  • Novartis
  • Merck
  • Pfizer
  • Bayer
  • Zoetis
  • Johnson
  • CSL
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Viral Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Viral Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Viral Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Viral Vaccines Market Dynamics
  1. 2.1 Viral Vaccines Industry Trends
  2. 2.2 Viral Vaccines Industry Drivers
  3. 2.3 Viral Vaccines Industry Opportunities and Challenges
  4. 2.4 Viral Vaccines Industry Restraints
3 Viral Vaccines Market by Company
  1. 3.1 Global Viral Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Viral Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Viral Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Viral Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Viral Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Viral Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Viral Vaccines Company Product Type and Application
  8. 3.8 Global Viral Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Viral Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Viral Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Viral Vaccines Market by Type
  1. 4.1 Viral Vaccines Type Introduction
  2. 4.1.1 Attenuated Vaccine
  3. 4.1.2 Inactivated Vaccine
  4. 4.2 Global Viral Vaccines Sales Volume by Type
  5. 4.2.1 Global Viral Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Viral Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Viral Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Viral Vaccines Sales Value by Type
  9. 4.3.1 Global Viral Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Viral Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Viral Vaccines Sales Value Share by Type (2021-2032)
5 Viral Vaccines Market by Application
  1. 5.1 Viral Vaccines Application Introduction
  2. 5.1.1 Research Institute
  3. 5.1.2 Hospital
  4. 5.1.3 Pharmaceutical Factory
  5. 5.1.4 Others
  6. 5.2 Global Viral Vaccines Sales Volume by Application
  7. 5.2.1 Global Viral Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Viral Vaccines Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Viral Vaccines Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Viral Vaccines Sales Value by Application
  11. 5.3.1 Global Viral Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Viral Vaccines Sales Value by Application (2021-2032)
  13. 5.3.3 Global Viral Vaccines Sales Value Share by Application (2021-2032)
6 Viral Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Viral Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Viral Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Viral Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Viral Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Viral Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Viral Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Viral Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Viral Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Viral Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Viral Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Viral Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Viral Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Viral Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Viral Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Viral Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Viral Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Viral Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Viral Vaccines Sales Value Share by Country, 2025 VS 2032
7 Viral Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Viral Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viral Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Viral Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Viral Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Viral Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Viral Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Viral Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Viral Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Viral Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Viral Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Viral Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Viral Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Viral Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Viral Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Viral Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Viral Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Viral Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Viral Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Viral Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Viral Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Viral Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Viral Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Viral Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Viral Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Viral Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Viral Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Viral Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Viral Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Viral Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Viral Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Viral Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Viral Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Viral Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Viral Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Viral Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Viral Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Viral Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Viral Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Viral Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Viral Vaccines Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Viral Vaccines Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Viral Vaccines Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Viral Vaccines Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Viral Vaccines Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Viral Vaccines Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Zoetis
  38. 8.7.1 Zoetis Company Information
  39. 8.7.2 Zoetis Business Overview
  40. 8.7.3 Zoetis Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zoetis Viral Vaccines Product Portfolio
  42. 8.7.5 Zoetis Recent Developments
  43. 8.8 Johnson
  44. 8.8.1 Johnson Company Information
  45. 8.8.2 Johnson Business Overview
  46. 8.8.3 Johnson Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Johnson Viral Vaccines Product Portfolio
  48. 8.8.5 Johnson Recent Developments
  49. 8.9 CSL
  50. 8.9.1 CSL Company Information
  51. 8.9.2 CSL Business Overview
  52. 8.9.3 CSL Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CSL Viral Vaccines Product Portfolio
  54. 8.9.5 CSL Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Viral Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Viral Vaccines Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Viral Vaccines Value Chain Analysis
  2. 9.1.1 Viral Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Viral Vaccines Sales Mode & Process
  6. 9.2 Viral Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Viral Vaccines Distributors
  9. 9.2.3 Viral Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst